Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer

RSC Advances ◽  
2016 ◽  
Vol 6 (48) ◽  
pp. 42109-42119 ◽  
Author(s):  
Gang Pan ◽  
Yi-jie Bao ◽  
Jie Xu ◽  
Tao Liu ◽  
Cheng Liu ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Anticancer Drug ◽  
Tumor Targeting ◽  
Polymeric Prodrug ◽  
Targeting Peptide ◽  
Covalently Linked ◽  
Tumor Targeting Peptide ◽  
Peptide Rgd

We report on the fabrication of a multifunctional polymeric prodrug covalently linked with an anticancer drug (bufalin, BUF) and tumor-targeting peptide (RGD) and investigate its anticancer performance against colon cancer in mice.

scholarly journals Doxorubicin-Loaded Tumor-Targeting Peptide-Decorated Polypeptide Nanoparticles for Treating Primary Orthotopic Colon Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Guoliang Liu ◽  
Min Wang ◽  
Hongyu He ◽  
Jiannan Li
Keyword(s):  
Colorectal Cancer ◽  
Drug Delivery ◽  
Colon Cancer ◽  
Disulfide Bonds ◽  
Tumor Targeting ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Antitumor Properties ◽  
Targeting Peptide ◽  
Tumor Targeting Peptide

Colorectal cancer is the third most common malignant disease worldwide, and chemotherapy has been the standard treatment for colorectal cancer. However, the therapeutic effects of chemotherapy are unsatisfactory for advanced and recurrent colorectal cancers. Thus, increasing the treatment efficacy of chemotherapy in colorectal cancer is a must. In this study, doxorubicin (DOX)-loaded tumor-targeting peptide-decorated mPEG-P(Phe-co-Cys) nanoparticles were developed to treat orthotopic colon cancer in mice. The peptide VATANST (STP) can specifically bind with vimentin highly expressed on the surface of colon cancer cells, thus achieving the tumor-targeting effects. The nanoparticles are core-shell structured, which can protect the loaded DOX while passing through the blood flow and increase the circulation time. The disulfide bonds within the nanoparticles are sensitive to the glutathione-rich microenvironment of tumor tissues. Rupture of disulfide bonds of the nanoparticles leads to the continuous release of DOX, thus resulting in the apoptosis of the tumor cells. The in vivo experiments in mice with orthotopic colon cancer demonstrated that the synthesized DOX-loaded tumor-targeting peptide-decorated polypeptide nanoparticles showed properties of drug delivery systems and exhibited good antitumor properties. The synthesized nanoparticles show appropriate properties as one of the drug delivery systems and exhibit good antitumor properties after encapsulating DOX.

A chimera of green fluorescent protein with gelatinase binding and tumor targeting peptide

2010 ◽  
Vol 72 (2) ◽  
pp. 234-237 ◽  
Author(s):  
Justus Reunanen ◽  
Tanja-Maria Ranta ◽  
Oula Peñate-Medina ◽  
Juho Suojanen ◽  
Timo Sorsa ◽  
...  
Keyword(s):  
Green Fluorescent Protein ◽  
Tumor Targeting ◽  
Fluorescent Protein ◽  
Targeting Peptide ◽  
Tumor Targeting Peptide ◽  
Green Fluorescent

scholarly journals Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma

Drug Delivery ◽  
2020 ◽  
Vol 27 (1) ◽  
pp. 1704-1717
Author(s):  
Renna Qiu ◽  
Denghua Sun ◽  
Yuzhuo Bai ◽  
Jiannan Li ◽  
Lizhe Wang
Keyword(s):  
Tumor Targeting ◽  
Targeting Peptide ◽  
Tumor Targeting Peptide

Tumor-Targeting Peptide for Redox-Responsive Pt Prodrug and Gene Codelivery and Synergistic Cancer Chemotherapy

2019 ◽  
Vol 2 (4) ◽  
pp. 1420-1426 ◽  
Author(s):  
Yaxuan Bai ◽  
Zeyu Li ◽  
Liping Liu ◽  
Tiedong Sun ◽  
Xiaocheng Fan ◽  
...  
Keyword(s):  
Cancer Chemotherapy ◽  
Tumor Targeting ◽  
Redox Responsive ◽  
Targeting Peptide ◽  
Tumor Targeting Peptide

Abstract 5518: Bladder tumor-targeting peptide-mediated anti-tumor activity of a pro-apoptotic peptide

2010 ◽  
Author(s):  
Hyun-Kyung Jung ◽  
Mi-Kyung Kwak ◽  
Eun-Ju Lee ◽  
Ji Woong Son ◽  
Rang-Woon Park ◽  
...  
Keyword(s):  
Tumor Targeting ◽  
Bladder Tumor ◽  
Targeting Peptide ◽  
Tumor Targeting Peptide ◽  
Anti Tumor Activity

TUMOR-TARGETING PEPTIDE-PNA-PEPTIDE CHIMERAS FOR IMAGING OVEREXPRESSED ONCOGENE mRNAS

2005 ◽  
Vol 24 (5-7) ◽  
pp. 1085-1091 ◽  
Author(s):  
X. Tian ◽  
M. R. Aruva ◽  
H. R. Wolfe ◽  
W. Qin ◽  
E. R. Sauter ◽  
...  
Keyword(s):  
Tumor Targeting ◽  
Targeting Peptide ◽  
Tumor Targeting Peptide

scholarly journals Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Jae Do Yoo ◽  
Sang Mun Bae ◽  
Junyoung Seo ◽  
In Seon Jeon ◽  
Sri Murugan Poongkavithai Vadevoo ◽  
...  
Keyword(s):  
Half Life ◽  
Tumor Targeting ◽  
Threefold Axis ◽  
Apoptosis Pathway ◽  
Cancer Models ◽  
Promising Target ◽  
Extrinsic Apoptosis ◽  
Targeting Peptide ◽  
Tumor Targeting Peptide

AbstractTRAIL is considered a promising target for cancer therapy because it mediates activation of the extrinsic apoptosis pathway in a tumor-specific manner by binding to and trimerizing its functional receptors, DR4 or DR5. Although recombinant human TRAIL has shown high potency and specificity for killing cancer cells in preclinical studies, it has failed in multiple clinical trials for several reasons, including a very short half-life mainly caused by instability of the monomeric form of TRAIL and rapid renal clearance of the off-targeted TRAIL. To overcome such obstacles, we developed a TRAIL-active trimer nanocage (TRAIL-ATNC) that presents the TRAIL ligand in its trimer-like conformation by connecting it to a triple helix sequence that links to the threefold axis of the ferritin nanocage. We also ligated the tumor-targeting peptide, IL4rP, to TRAIL-ATNC to enhance tumor targeting. The developed TRAIL-ATNCIL4rP showed enhanced agonistic activity compared with monomeric TRAIL. The in vivo serum half-life of TRAIL-ATNCIL4rP was ~ 16-times longer than that of native TRAIL. As a consequence of these properties, TRAIL-ATNCIL4rP exhibited efficacy as an anti-tumor agent in vivo against xenograft breast cancer as well as orthotopic pancreatic cancer models, highlighting the promise of this system for development as novel therapeutics against cancer.

Sign in / Sign up

Export Citation Format

Share Document